Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited has appointed James Vaughn as the new Chief Commercial Officer to enhance the global adoption of its Cxbladder diagnostic tests, following the inclusion of Cxbladder Triage in the American Urological Association guidelines. Vaughn’s extensive experience in the pharmaceutical and diagnostics sectors, including his success at Genomic Health, positions him to drive growth and market penetration for Pacific Edge, with a focus on increasing sales and improving reimbursement rates for its non-invasive bladder cancer tests.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. The company focuses on innovative solutions in the medical diagnostics industry, particularly targeting bladder cancer.
See more data about PFGTF stock on TipRanks’ Stock Analysis page.